Company intelligence / Profile preview
Aetas Pharma Inc.
Chiyoda-ku, Tokyo, Japanaetaspharma.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Phase 2
01
Overview
Aetas Pharma has completed Phase I studies demonstrating safety and effects on sodium diuresis and renal function in humans with mild renal dysfunction. As of November 2023, they have initiated Phase II clinical trials for their lead compound M201-A injection targeting patients with heart failure and renal dysfunction
- Therapeutic areas
- CardiovascularNephrology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major pharmaceutical or biotech partnerships disclosed; business strategy includes plans to license products domestically and internationally
Beyond the preview
Go deeper on Aetas Pharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aetas Pharma Inc..